« PERK activation mitigates tau pathology in vitro and in vivo« has been published in EMBO Molecular Medicine. This work was supported in part by JPND through the RiMOD‐FTD project, selected in the 2012 risk factors call.
février 6, 2017
« PERK activation mitigates tau pathology in vitro and in vivo« has been published in EMBO Molecular Medicine. This work was supported in part by JPND through the RiMOD‐FTD project, selected in the 2012 risk factors call.